Fund database › Private Equity
Mata Capital IMFR001400O770Class B-units
The MCF Access Feeder opens a buyout and fund-of-funds portfolio in Europe and North America through a French feeder structure, launched in 2024 — with no performance fee at feeder level.
A three-year lock-up, followed by quarterly redemption windows; investors exiting early after the release pay a time-limited penalty fee. The recommended holding period is eight years.
Subscription from EUR 100,000 for professional and semi-professional investors; not registered for distribution in Germany.
A niche provider alongside the global platforms: a lean feeder construction with clear lock-up logic instead of gate mechanics — more thinly documented than the rest of the field, with an ambitious objective.
Figures for class B-units (FR001400O770) · product data 19 Aug 2026 · sources: prospectus, PRIIPs-KID — full list under 08 documents.
No documented NAV series in the database.
What the prospectus permits: Feeder into the evergreen fund of funds 'Med Access' of ARCHIMED (internal fund of funds); growth/buyout
Taxonomy of semiliquid.info; only published values are used, nothing is estimated. The actual portfolio breakdown is in 03 Portfolio.
11 holdings; the five largest account for 51.8% of the fund. 33.0% is held in the liquidity reserve.
Focus according to fund documents: Healthcare & life sciences 100%
Focus according to fund documents: Global, not broken down 100%
Among the ten largest: 7 co-investments, 1 GP-led secondary, 1 primary fund; 3 names not disclosed.
ARCHIMED co-investment vehicle for ZimVie Inc., a US manufacturer of dental implants, biomaterials and digital dentistry solutions headquartered in Palm Beach Gardens (Florida).
ARK Diagnostics is a California-based manufacturer of in vitro diagnostic tests based on homogeneous enzyme immunoassays for therapeutic drug monitoring, for example of antiepileptic drugs …
Undisclosed ARCHIMED vehicle (co-investment or continuation vehicle) holding a stake in a French company in the animal and environmental health segment.
ARCHIMED co-investment vehicle for Jeisys Medical (Seoul), a manufacturer of energy-based devices for aesthetic dermatology, including high-intensity focused ultrasound …
ARCHIMED co-investment vehicle for Natus Neuro (neurodiagnostics, including EEG) and Natus Sensory (hearing and balance diagnostics, newborn hearing screening) …
ARCHIMED continuation vehicle for two life science service providers: Clean Biologics (France) offers biosafety testing and cell banking for biopharmaceutical manufacturers …
Undisclosed ARCHIMED vehicle holding a stake in a Danish consumer health company in the sun care and skin care segment.
MED Rise is the small-cap buyout fund of ARCHIMED (Lyon), 2024 vintage, targeting healthcare companies in Europe and North America.
LP interest in ARCHIMED's (Lyon) mid-cap buyout fund MED III, 2019 vintage, which invests in healthcare companies in Europe and North America.
Undisclosed co-investment vehicle (project name “Lighthouse”) holding a stake in a diagnostics company based in the Czech Republic.
Positions and shares according to the provider; 1 of 5 names not disclosed; short descriptions by semiliquid.info from public sources; Allocation according to the uniform semiliquid taxonomy; only published values are used, nothing is estimated.
With ongoing costs of 3.60%, class B-units is well above the median of the asset class (2.60%). There is no performance fee.
For 100,000 EUR this means roughly 3,600 EUR per year.
For 100,000 EUR, a one-off up to 5,000 EUR on purchase.
Based on the PRIIPs key information document of class B-units, hence comparable across providers. Median: 35 Private Equity funds in this database, data run 16 Oct 2026.
Subscription not documented. The prospectus dealing rules are not yet fully captured; therefore no date calculation, only the rules per prospectus.
| Frequency | not documented |
|---|---|
| Minimum investment | 100,000 EUR |
Data as at 19 Aug 2026 · Documents: 08.
Units can be redeemed quarterly — with a volume limit (Gate), lock-up 36 months. How quickly the money arrives and what happens if many want out at once is set out below.
No liquidity score — the redemption frequency cannot be determined from the prospectus.
The score needs a quantified redemption frequency, notice period and payout rule; as soon as the prospectus provides them, it is calculated.
| Frequency | quarterly |
|---|---|
| Gate | 5% NAV |
| Lock-up | 36 months |
5% of net assets
Data as at 19 Aug 2026 · Documents: 08.
1 class. All cost and risk figures on this page refer to the basis class B-units.
PRIIPs KID ✓: a key information document exists and is the source of the costs. —: no KID documented — the class is distributed outside the EEA or to investors not covered by the KID requirement, or the document is not available.
Who is behind the fund, where it may be distributed — and which documents were evaluated.
| Document | As at | Used for |
|---|---|---|
| Positions and reserve | 31 Dec 2025 | Portfolio (03) |
All figures are taken from provider documents (product data as at 16 Oct 2026, distribution data as at 5 Oct 2026) and have not been conclusively verified.
Redemption quarterly, with 5% gate.
Ongoing costs of 3.60% p.a. according to the PRIIPs KID for class B-units; the median of the Private Equity funds in this database is 2.60%; no performance fee.
100,000 EUR in class B-units.
As at 16 Oct 2026, no redemption restriction is documented for the MCF Access Feeder. Under the prospectus a gate of 5% applies.
Same asset class, similar sub-strategy.
Carmignac · ELTIF 2.0 · quarterly
Lexington Advisors, LLC · Part II UCI · quarterly
Sienna Gestion · FCPR · semi-monthly
Apollo Global Management · ELTIF 2.0 · quarterly
Liquidity score in the “as of today” view with average days to cash. No recommendation, no ranking.